China Pharmaceuticals and Healthcare Report Q4 2014 - New Report Available

A more 'rational' use of pharmaceuticals through pharmacoeconomics, and a crackdown on illegal rebates and corruption in China's pharmaceutical market could hinder the sector's growth potential. However, over the long term, the government is likely to improve its investment in healthcare in order to retain public support.

Headline Expenditure Projections

* Pharmaceuticals: CNY532.4bn (US$86.6bn) in 2013 to CNY616.1bn (US$99.3bn) in 2014; +15.7% in local currency and +14.7% in US dollar terms. Forecast broadly unchanged from Q 3 13.
* Healthcare: CNY3,230.8bn (US$525.4bn) in 2013 to CNY3,692.0bn (US$595.2bn) in 2014; +14.3% in local currency terms and +13.3% in US dollar terms. Forecast remains unchanged from Q313.

Risk/Reward Rating:

China's Pharmaceutical Risk/Reward Rating (RRR) score for Q414 is 64.4 out of the maximum 100 in our newly improved RRR system. The country scored above average for the majority of the indicators and sub-indicators, including overall market expenditure, sector value growth, patent respect and policy continuity. In this quarter, the country is ranked sixth, behind Hong Kong but in front of Singapore in the 19 key Asia Pacific markets.

Full Report Details at
- http://www.fastmr.com/prod/878947_china_pharmaceuticals_and_healthcare_report_q4.aspx?afid=301

Key Trends And Developments

* In August 2014, Shanghai Fosun Pharmaceutical Group, a leading healthcare company in China, announced plans to co-invest CNY680mn (USD110mn) with Taizhou City Investment through its wholly-owned subsidiary, Shanghai Medical Hospital Prudential Investment Management, to explore new cooperation models between the private sector and public hospitals. This is a significant development as it is the first of its type in China.
* In July 2014, China-based Yabao Pharmaceutical Group entered into a strategic partnership with US-based drugmaker Eli Lilly to co-develop Lilly's diabetes treatment glucokinase activator (GKA), LY2608204.
* In June 2014, GE Corporation announced the opening of a new healthcare facility in Tianjin, China, to better...

The China Pharmaceuticals and Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's China Pharmaceuticals and Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Chinese pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for China to test other views - a key input for successful budgeting and strategic business planning in the Chinese pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014